US 12,478,504 B2
Drug eluting ocular implants
David S. Haffner, Mission Viejo, CA (US); Kenneth M. Curry, Oceanside, CA (US); Harold A. Heitzmann, Irvine, CA (US); and David Applegate, Laguna Hills, CA (US)
Assigned to Glaukos Corporation, Aliso Viejo, CA (US)
Filed by Glaukos Corporation, Aliso Viejo, CA (US)
Filed on Dec. 13, 2024, as Appl. No. 18/980,392.
Application 18/980,392 is a continuation of application No. 17/219,102, filed on Mar. 31, 2021, granted, now 12,201,555.
Application 17/219,102 is a continuation of application No. 15/422,384, filed on Feb. 1, 2017, abandoned.
Application 15/422,384 is a continuation of application No. 13/321,144, abandoned, previously published as PCT/US2010/035319, filed on May 18, 2010.
Claims priority of provisional application 61/264,615, filed on Nov. 25, 2009.
Claims priority of provisional application 61/264,604, filed on Nov. 25, 2009.
Claims priority of provisional application 61/264,594, filed on Nov. 25, 2009.
Claims priority of provisional application 61/220,527, filed on Jun. 25, 2009.
Claims priority of provisional application 61/179,332, filed on May 18, 2009.
Prior Publication US 2025/0107929 A1, Apr. 3, 2025
Int. Cl. A61F 9/00 (2006.01); A61F 9/007 (2006.01); A61K 9/00 (2006.01)
CPC A61F 9/0017 (2013.01) [A61F 9/00781 (2013.01); A61K 9/0051 (2013.01); A61F 2210/0004 (2013.01); A61F 2250/0068 (2013.01)] 19 Claims
OG exemplary drawing
 
1. An ocular implant configured to deliver a drug within an eye of a subject, the ocular implant comprising:
an outer shell shaped to define an interior space, the outer shell comprising an opening;
a cap positioned at a proximal end of the outer shell;
a drug disposed within the interior space of the outer shell;
a permeable or semi-permeable material positioned at or near the opening of the outer shell, the permeable or semi-permeable material being permeable or semi-permeable to the drug so as to facilitate controlled elution of the drug within an anterior chamber of the eye; and
an anchor configured to affix a distal tip of the ocular implant into scleral tissue of the eye, wherein at least a portion of the anchor is configured to extend into the scleral tissue,
wherein the drug is travoprost.